What are the key financial results for Boston Scientific in the quarter ending June 29, 1997?

The provided text is a directory listing from the SEC EDGAR database and does not contain the actual financial statements or performance data. Therefore, specific financial results such as revenue, net income, or earnings per share for the quarter ending June 29, 1997, cannot be determined from this excerpt.

What is Boston Scientific Corporation's primary business?

Based on the context of SEC filings and general knowledge of the company, Boston Scientific Corporation is primarily involved in the development, manufacturing, and marketing of medical devices and technologies.

Where can I find the detailed financial information for this filing?

To access the detailed financial information, including the balance sheet, income statement, cash flow statement, and management's discussion and analysis, investors would need to obtain the full 10-Q filing document. This can typically be found on the SEC's EDGAR database by searching for the company's ticker symbol (BSX) and the filing date or form type.

What are the main risks or challenges Boston Scientific faced in 1997?

The provided text does not include information on specific risks or challenges. A review of the complete 10-Q filing, particularly the 'Risk Factors' section if available, would be necessary to identify the operational, market, or regulatory risks the company may have been facing at that time.

BSX 10-Q Quarterly Report Q2 FY1997 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) filed its quarterly report for the period ending June 29, 1997, on August 13, 1997. As this is a historical filing from 1997, specific financial performance metrics like revenue, net income, and cash flow are not directly available within the provided directory listing. The filing indicates that Boston Scientific is a company operating in the medical technology sector. Investors should note that without the actual financial statements and management's discussion and analysis (MD&A) from the 10-Q document, a detailed financial performance review is not possible. However, the filing serves as a regulatory update for the period. To understand the company's performance, investors would need to access the full 10-Q filing to review detailed financial data, operational highlights, risk factors, and any strategic developments that occurred during the second quarter of 1997.

Key Highlights

1Company: Boston Scientific Corporation (BSX)
2Filing Type: Quarterly Report (10-Q)
3Period End Date: June 29, 1997
4Filing Date: August 13, 1997
5Industry Focus: Medical Technology (inferred)
6Purpose: Regulatory disclosure of financial and operational information for the specified quarter.

BOSTON SCIENTIFIC CORP Quarterly Report for Q2 Ended Jun 30, 1997

Summary

Key Highlights

Frequently Asked Questions